These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19403380)

  • 1. [A simple and efficient method for establishing a mouse model of orthotopic MB49 bladder cancer].
    Liang ZK; Zhang L; Hu ZM; Chen Z; Huang X; Shi XH; Tan WL; Gao JM
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Apr; 29(4):627-30. PubMed ID: 19403380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing syngeneic orthotopic murine bladder cancer (MB49).
    Günther JH; Jurczok A; Wulf T; Brandau S; Deinert I; Jocham D; Böhle A
    Cancer Res; 1999 Jun; 59(12):2834-7. PubMed ID: 10383142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49).
    Günther JH; Frambach M; Deinert I; Brandau S; Jocham D; Böhle A
    J Urol; 1999 May; 161(5):1702-6. PubMed ID: 10210443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonviral cytokine gene therapy on an orthotopic bladder cancer model.
    Wu Q; Mahendran R; Esuvaranathan K
    Clin Cancer Res; 2003 Oct; 9(12):4522-8. PubMed ID: 14555526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel invasive orthotopic bladder cancer model with high cathepsin B activity resembling human bladder cancer.
    Lodillinsky C; Rodriguez V; Vauthay L; Sandes E; Casabé A; Eiján AM
    J Urol; 2009 Aug; 182(2):749-55. PubMed ID: 19539312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EDTA-induced urothelial cell shedding for the treatment of superficial bladder cancer in the mouse.
    Nativ O; Dalal E; Hidas G; Aronson M
    Int J Urol; 2006 Oct; 13(10):1344-6. PubMed ID: 17010016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing orthotopic bladder tumor implantation in a syngeneic mouse model.
    Chan ES; Patel AR; Smith AK; Klein JB; Thomas AA; Heston WD; Larchian WA
    J Urol; 2009 Dec; 182(6):2926-31. PubMed ID: 19846165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy.
    Loskog A; Ninalga C; Hedlund T; Alimohammadi M; Malmström PU; Tötterman TH
    Lab Anim; 2005 Oct; 39(4):384-93. PubMed ID: 16197705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin.
    Kawano H; Komaba S; Yamasaki T; Maeda M; Kimura Y; Maeda A; Kaneda Y
    Cancer Chemother Pharmacol; 2008 May; 61(6):973-8. PubMed ID: 17653716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring the response of orthotopic bladder tumors to granulocyte macrophage colony-stimulating factor therapy using the prostate-specific antigen gene as a reporter.
    Wu Q; Esuvaranathan K; Mahendran R
    Clin Cancer Res; 2004 Oct; 10(20):6977-84. PubMed ID: 15501977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The therapeutic potential of SA-sCD40L in the orthotopic model of superficial bladder cancer.
    Zhang Z; Xu X; Zhang X; Chen X; Chen Q; Dong L; Hu Z; Li J; Gao J
    Acta Oncol; 2011 Oct; 50(7):1111-8. PubMed ID: 21247263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-viral tumor necrosis factor-alpha gene transfer decreases the incidence of orthotopic bladder tumors.
    Zang Z; Mahendran R; Wu Q; Yong T; Esuvaranathan K
    Int J Mol Med; 2004 Oct; 14(4):713-7. PubMed ID: 15375606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GFP image analysis in the mouse orthotopic bladder cancer model.
    De Velasco MA; Tanaka M; Anai S; Tomioka A; Nishio K; Uemura H
    Oncol Rep; 2008 Sep; 20(3):543-7. PubMed ID: 18695904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
    Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
    J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intravesical perfusion of recombinant adeno-associated virus-endostatin in treatment of bladder cancer: experiments with mice].
    Lu BX; Han RF; Tang Y; Lei MD; Li SZ
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(44):3157-8. PubMed ID: 19159603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Characterization of a novel transplantable orthotopic nude mouse model with xenografted human bladder transitional cell tumor (BIU-87)].
    Li C; Yan RP; Yuan GH; Feng YG; Wang JS; Gao X; Huang YS; Zhou JB; Xie SS
    Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):733-6. PubMed ID: 17366782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.
    Pfost B; Seidl C; Autenrieth M; Saur D; Bruchertseifer F; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
    J Nucl Med; 2009 Oct; 50(10):1700-8. PubMed ID: 19793735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HAMLET treatment delays bladder cancer development.
    Mossberg AK; Hou Y; Svensson M; Holmqvist B; Svanborg C
    J Urol; 2010 Apr; 183(4):1590-7. PubMed ID: 20172551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin.
    Hadaschik BA; Adomat H; Fazli L; Fradet Y; Andersen RJ; Gleave ME; So AI
    Clin Cancer Res; 2008 Mar; 14(5):1510-8. PubMed ID: 18316576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immobilization of streptavidin-tagged bioactive hTNF-alpha on biotinylated mucosal surface of the bladder wall for treatment of superficial bladder cancer in mice].
    Chen Z; Tan WL; Huang X; Liang ZK; Xu CX; Gao JM
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 May; 30(5):936-40. PubMed ID: 20501361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.